Literature DB >> 1724684

Substance P and neurodegenerative disorders. A speculative review.

R Barker1.   

Abstract

The causes of the neurodegenerative disorders of Parkinson's disease (PD), Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS) are unknown. It is proposed that all these disorders result primarily from a loss of trophic peptidergic neurotransmitter, possibly Substance P (SP). This loss in turn produces the classical neuronal degeneration seen in each of these diseases and occurs due to a combination of natural aging and chronic autoimmune destruction following a viral infection of the CNS, early in life. The loss is therefore slow and by the time of clinical presentation the inflammatory process is disappearing as the antigenic stimulus lessens with its removal. The implications of the theory in terms of future research and therapy are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724684     DOI: 10.1016/0143-4179(91)90054-m

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  4 in total

Review 1.  Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.

Authors:  Inga Herpfer; Klaus Lieb
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization.

Authors:  N Froger; A M Gardier; R Moratalla; I Alberti; I Lena; C Boni; C De Felipe; N M Rupniak; S P Hunt; C Jacquot; M Hamon; L Lanfumey
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

Review 3.  Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity.

Authors:  J P Huston; R U Hasenöhrl; F Boix; P Gerhardt; R K Schwarting
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Using Gelatin Nanoparticle Mediated Intranasal Delivery of Neuropeptide Substance P to Enhance Neuro-Recovery in Hemiparkinsonian Rats.

Authors:  Ying-Zheng Zhao; Rong-Rong Jin; Wei Yang; Qi Xiang; Wen-Ze Yu; Qian Lin; Fu-Rong Tian; Kai-Li Mao; Chuan-Zhu Lv; Yi-Xiáng J Wáng; Cui-Tao Lu
Journal:  PLoS One       Date:  2016-02-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.